Salvador Leo Cevallos, MD
Psychiatry · South Daytona, FLNPI 1992926661
Payments from drug & device makers
Across 256 payments — averaging $18.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$988
- Otsuka America Pharmaceutical, Inc.$610
- Lundbeck LLC$428
- Tris Pharma Inc$324
- Corium, LLC$292
- Johnson & Johnson$272
- plus $2K from 17 others
What the payments were for
- Food & beverage$4,83599%
- Education$271%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 60 | $988 |
| Otsuka America Pharmaceutical, Inc. | 32 | $610 |
| Lundbeck LLC | 21 | $428 |
| Tris Pharma Inc | 16 | $324 |
| Corium, LLC | 14 | $292 |
| Johnson & Johnson | 11 | $272 |
| Alkermes, Inc. | 13 | $260 |
| Supernus Pharmaceuticals, Inc. | 13 | $241 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $231 |
| Ironshore Pharmaceuticals Inc. | 12 | $229 |
| Neurocrine Biosciences, Inc. | 11 | $221 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 11 | $220 |
| Axsome Therapeutics, Inc. | 6 | $162 |
| Collegium Pharmaceutical, Inc. | 5 | $92 |
| Avanir Pharmaceuticals, Inc. | 5 | $71 |
| E.r. Squibb & Sons, L.L.C. | 2 | $48 |
| Neuronetics, Inc. | 3 | $47 |
| Almatica Pharma LLC | 2 | $32 |
| Shire North American Group Inc | 1 | $25 |
| Eisai Inc. | 2 | $23 |
| Bausch Health US, LLC | 1 | $17 |
| Indivior Inc. | 1 | $16 |
| Alfasigma USA, Inc. | 1 | $12 |
How this compares
$4,862 in reported general payments places this provider in the 80th percentile of 2,059 psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Quetiapine Fumarate ErQuetiapine Fumarate | 16 | $1,194 |
| Duloxetine Hcl | 13 | $542 |
| Quetiapine Fumarate | 24 | $502 |
| Pregabalin | 19 | $485 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 12 | $267 |
| Trazodone Hcl | 39 | $247 |
| Clonazepam | 20 | $191 |
| Hydroxyzine Hcl | 11 | $163 |
| Divalproex Sodium | 14 | $140 |
| Lorazepam | 17 | $123 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in South Daytona
- Edwin GomezWeston$24.9M
- Rishi KakarTamarac$23.9M
- Peter VentreOakland Park$18.7M
- Jose GamezHialeah$14.8M
- John JoyceJacksonville$13.6M
- Silvia Silva-DulucMiami$11.7M
- Kelley WilsonTampa$11.1M
- Emilio Mantero-AtienzaMiami Beach$10.9M
- Patricia JunqueraMiami$10.8M
- Olga LapeyraLauderhill$10M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.